Raymond James Financial Services Advisors’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Raymond James Financial Services Advisors’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,197	Closed	-$10K	–	2991
2019 Q3	$10K	Sell	1,197 -435	-27%	-$3.24K	﹤0.01%	2779
2019 Q2	$11K	Sell	1,632 -300	-16%	-$2.57K	﹤0.01%	2818
2019 Q1	$16K	Buy	1,932 +250	+15%	+$2.58K	﹤0.01%	2758
2018 Q4	$27K	Buy	+1,682	New	+$37K	﹤0.01%	2505
2018 Q3	–	Sell	-1,152	Closed	-$26K	–	2928
2018 Q2	$26K	Buy	1,152 +85	+8%	+$2.02K	﹤0.01%	2711
2018 Q1	$31K	Sell	1,067 -68	-6%	-$1.99K	﹤0.01%	2469
2017 Q4	$32K	Buy	1,135 +110	+11%	+$3.42K	﹤0.01%	2463
2017 Q3	$37K	Buy	+1,025	New	+$31.7K	﹤0.01%	2475

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

XSC

X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Raymond James Financial Services Advisors's AVEO Position: Q4 2019 in Review

Raymond James Financial Services Advisors sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2019, closing a stake of 1,197 shares — an estimated $10K sold.

Raymond James Financial Services Advisors first reported a position in AVEO in Q3 2017 and held it in 8 quarters. The position peaked at $37K in Q3 2017. 61 funds tracked by Wall St. Rank hold AVEO as of Q4 2019.

Raymond James Financial Services Advisors reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
Raymond James Financial Services Advisors sold 1,197 AVEO Pharmaceuticals, Inc. shares in Q4 2019, an estimated $10K.
Raymond James Financial Services Advisors first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2017 and held it in 8 quarters.
Raymond James Financial Services Advisors's AVEO Pharmaceuticals, Inc. position peaked at $37K in Q3 2017.
61 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2019.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.